Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Operations: 2012-2025

Historic Cash from Operations for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to -$66.3 million.

  • Ptc Therapeutics' Cash from Operations rose 13.89% to -$66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $715.5 million, marking a year-over-year increase of 502.01%. This contributed to the annual value of -$107.7 million for FY2024, which is 32.02% up from last year.
  • Ptc Therapeutics' Cash from Operations amounted to -$66.3 million in Q3 2025, which was down 13.66% from -$58.3 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Cash from Operations peaked at $870.1 million during Q1 2025, and registered a low of -$166.0 million during Q4 2022.
  • Its 3-year average for Cash from Operations is $43.6 million, with a median of -$30.0 million in 2024.
  • In the last 5 years, Ptc Therapeutics' Cash from Operations slumped by 430.28% in 2024 and then surged by 1,129.64% in 2025.
  • Ptc Therapeutics' Cash from Operations (Quarterly) stood at -$68.8 million in 2021, then crashed by 141.09% to -$166.0 million in 2022, then soared by 39.57% to -$100.3 million in 2023, then skyrocketed by 70.08% to -$30.0 million in 2024, then rose by 13.89% to -$66.3 million in 2025.
  • Its Cash from Operations was -$66.3 million in Q3 2025, compared to -$58.3 million in Q2 2025 and $870.1 million in Q1 2025.